{"prompt": "['Aimmune Therapeutics, Inc.', 'AR101', 'ARC009 Protocol Amend 1.0', '11 Apr 2018 - FINAL', 'Aimmune Confidential Information', 'Page 57 of 122', 'Figure 3: Management of Study Product Dosing for Allergy Symptoms During', 'Up-Dosing and Maintenance', 'Dosing-Related Symptoms', 'Action', 'Dose under medical supervision to', 'determine tolerability.', 'or', 'Split home dose into 2 doses given', 'Next dose', '8-12 hours apart (only for recurrent', 'Uncertain if dose or', 'at home or', 'mild symptoms with home dosing).', 'dose level tolerated', 'at site per', 'or', 'investigator', 'Hold current dose level for 1-2 weeks', 'Mild', 'before attempting dose re-escalation.', 'symptoms', 'or', 'Reduce dose by 1 or 2 dose levels and', 'Dose or dose level not', 'Next dose', 'continue dosing at reduced level for at', 'tolerated', 'at site', 'least 2-4 weeks before attempting dose', 're-escalation.', 'Moderate', 'Not tolerated (with', 'Next dose', 'Reduce dose by 1 or 2 dose levels until', 'symptoms', 'rare exceptions) [1]', 'at site', 'tolerated with no or mild symptoms.', 'Reduce dose by 2 dose levels.', 'Not tolerated,', 'Next dose', 'If no or mild symptoms (assessed as', '0-1 dose of epinephrine', 'at site', 'tolerated) result, proceed with dosing at', 'reduced level for at least 2 weeks.', 'Severe', 'symptoms', 'Reduce dose by 2 dose levels if', 'continuation is safe. If no or mild', 'Not tolerated,', 'Next dose', 'symptoms (assessed as tolerated)', '2 doses of epinephrine', 'at site', 'result, proceed with dosing at reduced', 'level (if tolerated) for 6-8 weeks.', '[1] The actions for moderate symptoms assessed as tolerated are the same as for a dose or dose level', 'associated with mild symptoms assessed as tolerated.', 'Assess dose tolerability per Section 8.5.1.2.']['Aimmune Therapeutics, Inc.', 'AR101', 'ARC009 Protocol Amend 1.0', '11 Apr 2018 - FINAL', 'Aimmune Confidential Information', 'Page 58 of 122', 'Table 14: Description of Actions to Be Taken With Study Product Dosing for Allergy', 'Symptoms During Up-Dosing and Maintenance', 'Symptoms', 'Actions', 'Mild', 'For oral/pharyngeal pruritus occurring in isolation, continue the study product dose level', 'at home for the 2-week dosing interval, unless other symptoms develop.', 'For other mild symptoms and if the study product dose is assessed as tolerated', '(Section 8.5.1.2), repeat the same dose level the next day, ideally at the study site', 'although it may be given at home.', 'If no symptoms occur with the repeated dose, continue the dose level for the 2-week', 'dosing interval.', 'If mild symptoms occur with the repeated dose and the dose is assessed as tolerated,', 'continue the same dose level or reduce the dose to the previous tolerated dose level', 'for the 2-week dosing interval.', 'For other mild symptoms and if the study product dose is assessed as not tolerated', '(Section 8.5.1.2), give the previous tolerated dose level the next day at the study site.', 'If the reduced dose is tolerated, continue the dose level for the 2-week dosing', 'interval.', 'If the reduced dose is assessed as not tolerated, give a second reduced dose (1 or', '2 dose levels lower) the next day at the study site.', '-', 'If the second reduced dose is tolerated, continue this dose level for the 2-week', 'dosing interval.', '- If the second reduced dose is assessed as not tolerated, discuss early', 'discontinuation with the medical monitor.', '- If a third reduced dose is considered to be safe after discussion with the medical', 'monitor, give it at the study site under medical supervision. If the dose is assessed', 'as not tolerated, stop study product dosing and discontinue the subject early from', 'the study (Section 5.3).', 'For other mild symptoms and if the study product dose tolerability is uncertain, follow the', 'general guidance in this table for chronic or recurrent mild symptoms.', 'Mild', 'The recurrence of mild dose-related symptoms over several days of dosing at home may', '(chronic or', 'suggest that the study product dose level is not tolerated, even if each occurrence could be', 'recurrent)', 'assessed as tolerated.', 'For symptoms occurring > 4 times in a week, give the next dose of study product at', 'the study site to assess tolerability.', 'For symptoms occurring > 7 times during the 2-week dosing interval, the dose level', 'will be considered not tolerated (Section 8.5.1.2).', 'Other actions that may be taken for chronic or recurrent mild symptoms:', 'Continue daily dosing at home at the current dose level.', 'Continue the same daily dose for the rest of the 2-week dosing interval, split into', '2 portions (may be unequal) and given 8 to 12 hours apart.', 'Repeat the same dose level at the study site to assess tolerability.', 'Delay the dose escalation by 1 to 2 weeks.', 'Give the previous tolerated dose level (1 or 2 dose levels lower based on severity of', 'reaction) at the study site.', 'Stop study product dosing and discontinue the subject early from the study', '(Section 5.3).', 'GI symptoms', 'For chronic or recurrent GI symptoms, especially upper GI symptoms, a low threshold for', 'study product dose reduction and for considering early discontinuation is recommended', 'due to the potential for eosinophilic esophagitis. For dose-limiting chronic or recurrent GI']['Aimmune Therapeutics, Inc.', 'AR101', 'ARC009 Protocol Amend 1.0', '11 Apr 2018 - FINAL', 'Aimmune Confidential Information', 'Page 59 of 122', 'Symptoms', 'Actions', 'symptoms at doses < 20 mg/day, withhold study product for 4 weeks and resume at', '3 mg/day with the first dose given at the study site. If 3 mg/day is tolerated, continue this', 'dose level for at least 4 weeks before attempting re-escalation.', 'For dose-limiting chronic or recurrent GI symptoms at doses > 20 mg/day, follow the', 'general guidance in this table based on symptom severity.', 'Moderate', 'Administer the previous tolerated dose of study product the next day at the study site.', 'If no symptoms occur with the reduced dose, continue that dose level for 2 weeks', 'before attempting re-escalation.', 'If mild symptoms occur at the reduced dose, follow the guidelines for mild', 'symptoms.', 'If moderate symptoms occur at the reduced dose, give a second reduced dose (1 or', '2 dose levels lower) the next day at the study site.', '-', 'If the second reduced dose is tolerated, continue that dose level for at least 2 weeks', 'before attempting re-escalation.', '- If mild symptoms occur with the second reduced dose that is assessed as not', 'tolerated, follow the guidelines for mild symptoms.', '- If moderate symptoms recur at the second reduced dose, discuss early', 'discontinuation with the medical monitor.', 'If a third reduced dose is considered to be safe after discussion with the medical', 'monitor, give it at the study site under medical supervision. If the dose is', 'assessed as not tolerated, stop study product dosing and discontinue the subject', 'early from the study (Section 5.3).', 'In the rare case that a dose with moderate symptoms is assessed as tolerated, follow the', 'guidelines for mild symptoms and provide a brief explanation for the assessment on the', 'case report form.', 'Severe', 'Discuss early discontinuation with the medical monitor. If continuation of study product', 'is considered to be safe, administer a reduced dose at 2 dose levels the next day at the', 'study site under medical supervision. If the reduced dose is tolerated, continue that dose', 'level for at least 2 weeks before attempting re-escalation. If the reduced dose is assessed', 'as not tolerated, stop study product dosing and discontinue the subject early from the', 'study (Section 5.3).', 'Assess dose tolerability per Section 8.5.1.2.', 'GI, gastrointestinal.', 'Appropriate intervention for allergy symptoms associated with a new dose or dose level at', 'the study site or dosing at home will depend on the type and severity of symptoms. The', 'process algorithm for dose adjustments after administration of antihistamines and', 'epinephrine for dose-related allergy symptoms at the study site or at home during up-dosing', 'and maintenance is described in Table 15.']", "completion": ""}